Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

849 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors: A Review.
Horbinski C, Solomon DA, Lukas RV, Packer RJ, Brastianos P, Wen PY, Snuderl M, Berger MS, Chang S, Fouladi M, Phillips JJ, Nabors B, Brat DJ, Huse JT, Aldape K, Sarkaria JN, Holdhoff M, Burns TC, Peters KB, Mellinghoff IK, Arons D, Galanis E. Horbinski C, et al. Among authors: berger ms. JAMA Oncol. 2024 Dec 26. doi: 10.1001/jamaoncol.2024.5506. Online ahead of print. JAMA Oncol. 2024. PMID: 39724142
Level I and II deficits-A clinical survey on international practice of awake craniotomy and definitions of postoperative "major" and "minor" deficits.
Vooijs M, Robertson FC, Blitz SE, Jungk C, Krieg SM, Schucht P, De Vleeschouwer S, Vincent AJPE, Berger MS, Nahed BV, Broekman MLD, Gerritsen JKW. Vooijs M, et al. Among authors: berger ms. Neurooncol Adv. 2024 Nov 30;6(1):vdae206. doi: 10.1093/noajnl/vdae206. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 39687790 Free PMC article.
Analysis of the Porphyrin Peak Shift and Fluorescence Lifetime in Gliomas with Different Tumor Grades, Intratumoral Regions, and Visible Fluorescence Status.
Körner LI, Reichert D, Andreana M, Unterhuber A, Erkkilae MT, Makolli J, Kiesel B, Mischkulnig M, Rötzer-Pejrimovsky T, Wöhrer A, Berger MS, Leitgeb R, Widhalm G. Körner LI, et al. Among authors: berger ms. Diagnostics (Basel). 2024 Nov 25;14(23):2651. doi: 10.3390/diagnostics14232651. Diagnostics (Basel). 2024. PMID: 39682559 Free PMC article.
Practical and statistical aspects of subgroup analyses in surgical neuro-oncology: A comprehensive review from the PIONEER Consortium.
Gerritsen JKW, Karschnia P, Young JS, van den Bent MJ, Chang SM, Smith TR, Nahed BV, Rincon-Torroella J, Bettegowda C, Sanai N, Krieg SM, Maruyama T, Schucht P, Broekman MLD, Tonn JC, Wen PY, De Vleeschouwer S, Vincent AJPE, Hervey-Jumper S, Berger MS, Mekary RA, Molinaro AM. Gerritsen JKW, et al. Among authors: berger ms. Neuro Oncol. 2024 Dec 7:noae261. doi: 10.1093/neuonc/noae261. Online ahead of print. Neuro Oncol. 2024. PMID: 39657588
Editor's Note: BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
Olow A, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss W, Resnick AC, Waanders AJ, Stalpers LJA, Berger MS, Gupta N, James CD, Petritsch CK, Haas-Kogan DA. Olow A, et al. Among authors: berger ms. Clin Cancer Res. 2024 Dec 2;30(23):5494. doi: 10.1158/1078-0432.CCR-24-3478. Clin Cancer Res. 2024. PMID: 39618199 No abstract available.
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses.
Lucas CG, Al-Adli NN, Young JS, Gupta R, Morshed RA, Wu J, Ravindranathan A, Shai A, Oberheim Bush NA, Taylor JW, de Groot J, Villanueva-Meyer JE, Pekmezci M, Perry A, Bollen AW, Theodosopoulos PV, Aghi MK, Chang EF, Hervey-Jumper SL, Raleigh DR, Molinaro AM, Costello JF, Diaz AA, Clarke JL, Butowski NA, Phillips JJ, Chang SM, Berger MS, Solomon DA. Lucas CG, et al. Among authors: berger ms. Neuro Oncol. 2024 Nov 19:noae214. doi: 10.1093/neuonc/noae214. Online ahead of print. Neuro Oncol. 2024. PMID: 39560080
The impact of intraoperative mapping during re-resection in recurrent gliomas: a systematic review.
van Opijnen MP, Sadigh Y, Dijkstra ME, Young JS, Krieg SM, Ille S, Sanai N, Rincon-Torroella J, Maruyama T, Schucht P, Smith TR, Nahed BV, Broekman MLD, De Vleeschouwer S, Berger MS, Vincent AJPE, Gerritsen JKW. van Opijnen MP, et al. Among authors: berger ms. J Neurooncol. 2024 Nov 18. doi: 10.1007/s11060-024-04874-1. Online ahead of print. J Neurooncol. 2024. PMID: 39556284 Review.
Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: a report of the RANO resect group.
Karschnia P, Young JS, Youssef GC, Dono A, Häni L, Sciortino T, Bruno F, Juenger ST, Teske N, Dietrich J, Weller M, Vogelbaum MA, van den Bent M, Beck J, Thon N, Gerritsen JKW, Hervey-Jumper S, Cahill DP, Chang SM, Rudà R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, Huang RY, Wen PY, Berger MS, Molinaro AM, Tonn JC; RANO resect group. Karschnia P, et al. Among authors: berger ms. Neuro Oncol. 2024 Nov 4:noae231. doi: 10.1093/neuonc/noae231. Online ahead of print. Neuro Oncol. 2024. PMID: 39492786
849 results